semaglutide russia The Ministry of Health has registered Russia's seventh drug with Weight-loss jab could be made

Tirzepatide's dual GIP/GLP-1 mechanism showed up to 22% weight loss in clinical trials of brand-name tirzepatide

Clinical standardization remains absent, and formulation quality varies significantly between sources

Sometimes, it may be the only symptom, or an early symptom

As First-Line Treatment Guidelines increasingly support GLP-1 agonists as first-line treatment alongside or instead of metformin: When to consider first-line GLP-1: Established cardiovascular disease High cardiovascular risk Significant obesity (BMI 35+) Strong desire for weight loss Insurance coverage available Traditional metformin-first approach: Lower cost without insurance Decades of safety data Effective for many patients Can add GLP-1 later if needed For many patients, starting with a GLP-1 medication rather than metformin provides superior comprehensive benefit